A perfusion culture system using a stirred ceramic membrane reactor for hyperproduction of IgG2a monoclonal antibody by hybridoma cells
- PMID: 15903251
- DOI: 10.1021/bp049826l
A perfusion culture system using a stirred ceramic membrane reactor for hyperproduction of IgG2a monoclonal antibody by hybridoma cells
Abstract
A novel perfusion culture system for efficient production of IgG2a monoclonal antibody (mAb) by hybridoma cells was developed. A ceramic membrane module was constructed and used as a cell retention device installed in a conventional stirred-tank reactor during the perfusion culture. Furthermore, the significance of the control strategy of perfusion rate (volume of fresh medium/working volume of reactor/day, vvd) was investigated. With the highest increasing rate (deltaD, vvd per day, vvdd) of perfusion rate, the maximal viable cell density of 3.5 x 10(7) cells/mL was obtained within 6 days without any limitation and the cell viability was maintained above 95%. At lower deltaD's, the cell growth became limited. Under nutrient-limited condition, the specific cell growth rate (mu) was regulated by deltaD. During the nonlimited growth phase, the specific mAb production rate (qmAb) remained constant at 0.26 +/- 0.02 pg/cell x h in all runs. During the cell growth-limited phase, qmAb was regulated by deltaD within the range of 0.25-0.65 vvdd. Under optimal conditions, qmAb of 0.80 and 2.15 pg/cell x h was obtained during the growth-limited phase and stationary phase, respectively. The overall productivity and yield were 690 mg/L x day and 340 mg/L x medium, respectively. This study demonstrated that this novel perfusion culture system for suspension mammalian cells can support high cell density and efficient mAb production and that deltaD is an important control parameter to regulate and achieve high mAb production.
Similar articles
-
Perfusion culture of hybridoma cells for hyperproduction of IgG(2a) monoclonal antibody in a wave bioreactor-perfusion culture system.Biotechnol Prog. 2007 Jan-Feb;23(1):255-64. doi: 10.1021/bp060299a. Biotechnol Prog. 2007. PMID: 17269696
-
The production of monoclonal antibody in growth-arrested hybridomas cultivated in suspension and immobilized modes.Biotechnol Prog. 1999 Jul-Aug;15(4):655-66. doi: 10.1021/bp990068m. Biotechnol Prog. 1999. PMID: 10441357
-
On-line purification of monoclonal antibodies using an integrated stirred-tank reactor/expanded-bed adsorption system.Biotechnol Prog. 2002 Nov-Dec;18(6):1292-300. doi: 10.1021/bp025543m. Biotechnol Prog. 2002. PMID: 12467465
-
Monoclonal antibody: high density culture of hybridoma cells and downstream processing for IgG recovery.Indian J Exp Biol. 1998 Feb;36(2):125-35. Indian J Exp Biol. 1998. PMID: 9754040 Review.
-
Getting higher yields of monoclonal antibody in culture.Indian J Physiol Pharmacol. 1998 Apr;42(2):155-71. Indian J Physiol Pharmacol. 1998. PMID: 10225044 Review.
Cited by
-
Trends in Monoclonal Antibody Production Using Various Bioreactor Syst.J Microbiol Biotechnol. 2021 Mar 28;31(3):349-357. doi: 10.4014/jmb.1911.11066. J Microbiol Biotechnol. 2021. PMID: 32238761 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials